Severity score for hereditary hemorrhagic telangiectasia. by Latino, GA et al.
UCSF
UC San Francisco Previously Published Works
Title
Severity score for hereditary hemorrhagic telangiectasia.
Permalink
https://escholarship.org/uc/item/5vf4n9qh
Journal
Orphanet J Rare Dis, 9(1)
ISSN
1750-1172
Authors
Latino, GA
Kim, H
Nelson, J
et al.
Publication Date
2014-12-01
DOI
10.1186/s13023-014-0188-3
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Latino et al. Orphanet Journal of Rare Diseases  (2014) 9:188 
DOI 10.1186/s13023-014-0188-3RESEARCH Open AccessSeverity score for hereditary hemorrhagic
telangiectasia
Giuseppe A Latino1,2*, Helen Kim3,4, Jeffrey Nelson3, Ludmila Pawlikowska3,4, William Young3ˆ, Marie E Faughnan2,5
and the Brain Vascular Malformation Consortium HHT Investigator GroupAbstract
Background: A disease severity score in hereditary hemorrhagic telangiectasia (HHT) would be a useful tool for
assessing burden of disease and for designing clinical trials. Here, we propose the first known HHT severity score,
the HHT-score.
Methods: Demographics and disease characteristics were collected for the first 525 HHT patients recruited to the
HHT Project of the Brain Vascular Malformation Consortium (BVMC). HHT-score was calculated based on presence
of: organ arteriovenous malformations (maximum 3 points); chronic bleeding (maximum 2 points); and severe organ
involvement (maximum 2 points). Points were summed and patients categorized as having mild (0–2), moderate
(3–4) or severe (5–7) disease. The occurrence of “any adverse outcome” was evaluated for association with
HHT-score categories.
Results: The frequency of “any adverse outcome” was significantly different across the three groups (49.6% in mild,
65.8% in moderate and 89.5% in severe, p < 0.001). Adjusting for age and gender, the risk of “any adverse outcome”
was higher in the moderate (OR = 1.84, 95% CI: 1.15-2.95, p = 0.011) and severe groups (OR = 9.16, 95% CI: 1.99-42.09,
p = 0.004) compared to the mild.
Conclusions: We have taken the first steps toward creating a global measure of disease severity in HHT. While the
initial results are promising, further validation of the HHT-score is still required.
Keywords: Hereditary Hemorrhagic Telangiectasia (HHT), Osler-Weber-Rendu, Arteriovenous Malformation (AVM),
Bleeding, Disease severity, Severity scoreBackground
Hereditary hemorrhagic telangiectasia (HHT) is an
autosomal dominant condition of vascular dysplasia
characterized by mucocutaneous telangiectases and organ
arteriovenous malformations (AVMs) mainly affecting the
lungs, liver and brain [1,2]. To date, mutations in three
different genes have been identified, all coding for proteins
of the TGF-β/BMP-9 signalling pathway. The two most
commonly mutated genes are endoglin (ENG or HHT1)
and activin A receptor type II-like 1 (ALK-1 or HHT2) [1],* Correspondence: giuseppejoey.latino@sickkids.ca
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unless otherwise stated.with SMAD4 mutations reported in a small subset of pa-
tients, most of whom also have juvenile polyposis [1,3].
HHT is thought to affect at least 1 in 10000 individuals
with no known ethnic predisposition [1,2,4-8].
Telangiectases and AVMs are prone to bleeding, leading
to chronic epistaxis and/or gastrointestinal (GI) bleeding
in most HHT patients, and a risk of life-threatening pul-
monary or cerebral hemorrhage in approximately 50%
[1,9,10]. Patients may also develop potentially fatal com-
plications from arteriovenous shunting, including stroke,
brain abscess and high-output cardiac failure [1,9,10].
While the penetrance of HHT is very high, there is
wide variability in disease expression and severity [1]. To
date, there is no global measure of disease severity in
HHT, which affects multiple organ systems. Although an
epistaxis severity score (ESS) is available for this symptom
of HHT [11], there is currently no overall HHT severityThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of disease, for stratifying patients and for research study
design. In fact, the development of disease severity mea-
sures has been identified as a research priority by the
HHT Foundation International [12]. Here, we present the
first HHT severity score (HHT-score), incorporating organ
involvement and chronic bleeding, and evaluated whether
HHT-scores are associated with adverse outcomes.
Methods
The Brain Vascular Malformation Consortium (BMVC) HHT
project
The Brain Vascular Malformation Consortium (BVMC)
is an integrated group of academic medical centers, pa-
tient support organizations, and clinical research re-
sources focused on clinical research on brain vascular
malformations and improving care for patients with
HHT, Sturge-Weber syndrome and Familial Cavernous
Malformations. Each of the three study groups has
established scalable relational databases for observational
and longitudinal studies.
The HHT project of the BVMC represents the first
large-scale multicenter global collaboration in HHT re-
search, including fourteen HHT centres of excellence in
Canada, the US and Europe. Between June 2010 and
January 2013, comprehensive data was collected for 525
recruited HHT patients, 129 of whom have BAVMs. The
population characteristics of the cohort are similar to
those reported in the literature for unselected HHT pop-
ulations [13]. While the database was primarily created
for the study of BAVMs and ICH, it was intended to also
serve as a platform to foster HHT research in other
non-BAVM related projects.
Study population
We performed a retrospective cross-sectional review of
the first 525 patients with HHT recruited to the HHT
Project of the BVMC. Recruited patients had been screened
for organ involvement and other clinical features according
to routine clinical practice in HHT Centers of Excellence.
The routine initial assessment of HHT patients seen at
the 14 participating HHT Centers included: a comprehen-
sive history and physical for symptoms and complications
of HHT, screening for PAVMs (contrast echocardiography
and confirmatory computed tomography (CT) for all
positive echocardiography results), screening for BAVMs
(cerebral magnetic resonance imaging with use of contrast
variable among centers), clinical screening for recurrent
spontaneous epistaxis (>1 episode per month for >1 year),
HHT-related GI-bleeding (anemia, iron deficiency, known
GI telangiectases on endoscopy, melena, rectal bleeding),
clinical screening for liver VMs (clinical symptoms includ-
ing chronic right upper quadrant pain, complications such
as portal hypertension, high-output heart failure, liverbruit on examination, abnormal liver function tests) as well
as routine blood work (complete blood count, ferritin).
When initial screening was positive for PAVMs or BAVMs,
patients underwent diagnostic imaging and preventative
treatment, where appropriate, according to International
HHT Guidelines [1]. If initial clinical assessment was
suggestive of HHT-related GI bleeding, then diagnostic
endoscopy was recommended, and endoscopic, medical
and supportive therapies were undertaken on a case-by-
case basis. If initial clinical assessment was suggestive of
symptomatic liver VMs, then diagnostic imaging was
recommended and supportive therapy was also under-
taken on a case-by case basis.
Data collected included age, sex, HHT mutation type,
clinical presentation and symptoms, presence of AVMs
on imaging, and outcomes. Those with incomplete data
were excluded, as well as pediatric patients (≤18 years
old) because of the small number of patients recruited
to date. All patients provided written, informed consent
and the study protocol was approved by individual re-
search ethics board at each center.HHT-score definition
An HHT-score was developed based on organ involve-
ment and the presence of chronic bleeding. The score
elements were proposed a priori from clinical expertise
(MEF, GAL) and were assigned a numerical value based
on their assumed impact on disease severity (Figure 1).
Chronic bleeding was assigned a score of 1 point each for
nasal and GI bleeding. A score of 1 point was received for
each organ affected by AVMs, up to a maximum of 3
points. The presence of PAVMs was given 1 point only
if AVMs were confirmed on CT thorax. Lastly, given the
greater perceived impact of certain severe phenotypes of
organ involvement on outcomes in HHT, 2 points were
given to patients with diffuse PAVMs and/or symptom-
atic liver involvement. Diffuse PAVMs were defined as
AVMs involving every subsegmental artery of at least
one lobe.
Total points were tallied for each patient with a pos-
sible minimum score of 0 to a maximum of 7. Based on
the calculated values, patients were arbitrarily catego-
rized as having mild disease for a score of 0 to 2, mod-
erate disease for a score of 3 to 4, and severe disease
for a score of 5 to 7.Adverse outcomes
We defined “any adverse outcome” as the presence of
any one of the following typical HHT-related severe
adverse outcomes: stroke, intracranial hemorrhage (ICH),
seizure, anemia (as obtained on medical history), blood
transfusion, massive hemoptysis, hemothorax, brain ab-
scess, and death.
Figure 1 Definition of the proposed HHT-score.
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We tested for an association between severity score cat-
egories and any adverse outcome using Fisher’s exact
test. Logistic regression analysis was also performed to
test whether moderate and severe severity score categories
were significant predictors of an adverse outcome when
compared to the mild group. Odds ratios (OR) and 95%
confidence intervals (CI) are reported and results are fur-
ther adjusted for age and gender. An alpha of 0.05 was
used to determine statistical significance. All analyses were
conducted with Stata version 12.1 [14].
Results
Of the initial 525 HHT patients, 393 patients (74.9%)
were included in the analysis and 132 individuals were
excluded (47 pediatric patients, 85 adult patients with
incomplete data). The majority of patients were female
(65.1%) with a mean age of 49.2 ± 14.3 years. Of those
with a confirmed genetic diagnosis of HHT, 54 (33.3%)
had an ALK-1 mutation, 101 (62.4%) had an ENG muta-
tion, and 7 (4.3%) had a SMAD4 mutation. The remaining
patients all had a definite clinical diagnosis of HHT, but
either had negative HHT gene mutation testing (no muta-
tion identified) or had not undergone genetic testing given
their known clinical diagnosis. The majority of patients
had a history of recurrent spontaneous epistaxis (381 or
97.0%); GI bleeding was present in 66 (16.8%), PAVMs in
200 (50.9%), BAVMs in 91 (23.2%), and diagnosed liver
VMs in 83 (21.1%) patients. The clinical characteristics of
HHT patients enrolled in the BVMC study were similar topreviously published series [1,11,13,15-23], with the ex-
pected exception of a higher prevalence of BAVMs, as per
BVMC study recruitment protocol.
After HHT-scores were assigned, 260 (66.2%) of the
included patients were categorized as having mild dis-
ease (HHT-score 0–2), while 114 (29.0%) and 19 (4.8%)
patients had moderate (HHT-score 3–4) and severe
disease (HHT-score 5–7), respectively. The frequency
of any adverse outcome was significantly different
across the severity groups (49.6% for mild, 65.8% for
moderate, and 89.5% for severe, p < 0.001). The most
common adverse outcomes were anemia, need for blood
transfusion and stroke for all three severity score categor-
ies (Figure 2). Even when removing anemia and blood
transfusions as outcomes in the analysis, the frequency of
any adverse outcomes remained significantly different
across the three severity groups (p < 0.01).
Modeling the severity groups as categorical variables,
both the moderate group (OR = 1.95, 95% CI: 1.24-3.08,
p = 0.004) and the severe group (OR = 8.63, 95% CI:
1.95-38.11, p = 0.004) were significantly more likely to
have had an adverse outcome compared to the mild group.
This once again held true even when excluding anemia and
blood transfusions from the analysis. In univariable logistic
regression analysis, age (per decade) was found to be
associated with any adverse outcomes (OR = 1.43, 95%
CI: 1.23-1.66, p < 0.001), and gender was not (OR = 1.15,
95% CI: 0.76-1.74, p = 0.517). However, even after adjust-
ing for age and gender, the OR estimates for severity score
categories remained significant for the moderate group
Figure 2 The frequency of “any adverse outcome” in patients with a mild, moderate and severe HHT-score. The frequency of “any
adverse outcome” is significantly different across the three severity groups (p < 0.001) and there is a clear “dose-dependent” curve. The
frequencies of individual adverse outcomes are shown within each bar for the respective severity groups. Absolute frequencies are provided and
their relative frequencies, as percentages, in brackets. Note that “lung hemorrhage” includes massive hemoptysis and spontaneous hemothorax.
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group (OR = 9.16, 95% CI: 1.99-42.09, p = 0.004) com-
pared to the mild severity group, and similar to the un-
adjusted estimates.
Discussion
We present here the first overall severity score for HHT,
the HHT-score, developed in a well-characterized, multi-
center cohort of 393 adult HHT patients. We demonstrate
that higher HHT-scores are associated with higher fre-
quencies of adverse outcomes. The HHT-score provides a
standardized method of categorizing disease severity in
adults and, as such, would help to assess burden of disease
and guide clinical trial design.
The frequency of “any adverse outcome” was found to
increase significantly with higher HHT-scores, providing
preliminary evidence of the validity of the HHT-score
for classifying patients by worsening disease severity and
for predicting risk of adverse outcome. While increas-
ing age was associated with higher frequency of severe
outcomes, neither age nor gender was found to signifi-
cantly affect the relationship between HHT-score and
risk of adverse outcomes in our logistic regression
model. Although the frequency of any adverse outcome
may appear higher than expected, especially in themild group, it is easily explained by the study design,
given that we collected the adverse outcomes over the
patients’ entire lifetime. We justified this approach on
the grounds that the disease is present at birth, often
many years before diagnosis, and that recorded outcomes
should therefore not be restricted to the period of time
after diagnosis. In addition, we were reassured by the
“dose–response” curve of the frequency of any adverse
outcome with HHT-scores, which has good face validity.
One of the strengths of the HHT-score is that it incor-
porates a comprehensive set of clinical manifestations of
the disease from epistaxis to BAVMs, and is simple to
apply after routine clinical assessment of an HHT pa-
tient. Though it may not seem intuitive to amalgamate
everything from epistaxis to BAVMs into a severity
score, it is biologically plausible that there are common
mechanisms and/or modifiers for the development of
hemorrhage from vascular malformations across organs.
The observed scores were reasonably distributed across
the severity categories, roughly compatible with our clin-
ical experience, though we might have expected a slightly
higher percentage (~10%) of patients to have scored in the
severe category. We speculate that this may be rectified in
the future by including additional criteria for severe organ
involvement that were not readily available from the
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BAVMs, extreme multiplicity of GI telangiectases, pres-
ence of juvenile polyposis, pulmonary hypertension, ESS,
pulmonary shunt grade, etc. One other strength of the
HHT-score is the generalizability of the results; not only
were the clinical characteristics of the study cohort similar
to those reported in other HHT series in the literature,
but the patients also came from multiple centres rather
than a single centre.
While data pertaining to pulmonary shunt grades was
not collected in this study, its incorporation into future
versions of the HHT-score may prove especially useful.
There is a growing body of literature on the utility of
pulmonary shunt grades in HHT [24-28]. Patients with
shunting on bubble echocardiography sometimes do not
have detectable PAVMs on CT thorax, and this is thought
to be related to either false positive results or microAVMs
that are too small to be detected on CT [24,25]. In fact, re-
cent studies have shown that of all HHT patients with
grade 1 shunting, which makes up the majority of patients
with a positive bubble echo but negative CT, none have
PAVMs large enough for embolization [25,26]. Further-
more, individuals with HHT and grade 1 shunting are not
at an elevated risk of cerebral complications [27]. This
suggests that while some patients in our cohort may have
had PAVMs too small to be detected on CT thorax, it
should be of little to no clinical consequences. In contrast,
patients with grade ≥2 pulmonary shunt grades are
significantly more likely to have detectable PAVMs
resulting in clinical complications [27], highlighting
the possible value of using pulmonary shunt grade as
a measure of severe organ involvement in future ver-
sions of the HHT-score.
This study is limited by its retrospective nature and
the associated biases. Complete data from the medical
chart was not always available, resulting in the exclusion
of several patients if the maximum possible HHT-score
could not be calculated. While the cross-sectional design
does not allow us to draw conclusions related to causality,
this was not our goal. Given the deliberate design by
which patients were recruited (i.e. 3 HHT patients with
no BAVMs for every 1 HHT patient with a BAVM), there
was a slight overrepresentation of patients with BAVMs.
While including more patients with BAVMs may theoret-
ically increase our overall estimates of adverse outcomes,
BAVM-related adverse outcomes comprised only a small
percentage of the total adverse outcomes for each severity
group, and therefore the overrepresentation of BAVMs is
unlikely to have influenced our results. Otherwise, the
clinical characteristics of our sample were very similar to
those of other reported HHT populations. The items,
scoring system and score ranges were defined based on
expert clinical opinion, rather than a formal item gener-
ation process, which might limit generalizability, thoughthe preliminary data is reassuring. Evidently, the HHT-
score will require further assessment, including valid-
ation in other cohorts and by other investigators and
stake-holders, and may require revisions. In addition,
there are other clinical factors that may impact disease
outcomes in HHT, which could be incorporated into
future versions of the HHT-score, such as age, other
organs affected by AVMs and further criteria for severe
organ involvement as described above. The applicability of
the HHT-score to children has also yet been tested and
further studies in a pediatric HHT population are needed.Conclusions
In summary, we have developed the first overall disease
severity score for HHT, and have associated HHT-scores
with more frequent adverse outcomes. The HHT-score
provides a standardized method of categorizing disease
severity in adults and, as such, would help to assess
burden of disease and guide clinical trial design. While
preliminary results are encouraging, further validation
studies are required, as well as prospective studies
assessing the predictive power of the score and delineating
the HHT-score to children has also not yet been tested
and adverse outcomes.
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